Assessment Of Soluble Fas Ligand In Patients With Chronic Myeloid Leukemia

Background: Soluble FasL (sFasL) generating from Membrane-bound (mFasL) cleaved by matrix metalloproteinases (MMPs). sFasL inhibits the apoptotic and inflammatory activity of mFasL because competes with binds to Fas. To evaluate serum soluble Fas ligand level in patients chronic myeloid leukemia.
 Materials Method: Serum levels were measured ELISA method after venous blood was collected 56 CML (newly diagnosed optimally treated) 28 healthy subjects as control group.
 Results: There no significant increases patient compared P=0.07. When mean concentration obviously highest newly (216.9pg/ml) followed (152.5pg/ml) lowest treated (147.7 pg/ml).
 Conclusion: Production tumor may be a key mechanism inhibit Fas-mediated apoptosis.